916179-87-8 Usage
Uses
Used in Pharmaceutical Synthesis:
3-Bromoindole-5-carboxylic acid is used as a starting material for the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows for the creation of a wide range of bioactive molecules, making it a valuable component in drug development.
Used in Antimicrobial Applications:
In the field of microbiology, 3-Bromoindole-5-carboxylic acid is utilized as an antimicrobial agent. Its ability to inhibit the growth of certain microorganisms makes it a potential candidate for use in treatments and preventative measures against bacterial and fungal infections.
Used in Anticancer Research:
3-Bromoindole-5-carboxylic acid is used as an intermediate in the production of drugs with anticancer properties. Its potential to target and affect cancer cells has positioned it as a subject of interest in oncology research, with the aim of developing new therapeutic agents for cancer treatment.
Used in Bioactive Molecule Production:
3-Bromoindole-5-carboxylic acid is employed as a precursor in the synthesis of bioactive molecules. Its versatility in chemical reactions facilitates the creation of compounds with specific biological activities, which can be applied in various industries, including pharmaceuticals and cosmetics.
Check Digit Verification of cas no
The CAS Registry Mumber 916179-87-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,6,1,7 and 9 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 916179-87:
(8*9)+(7*1)+(6*6)+(5*1)+(4*7)+(3*9)+(2*8)+(1*7)=198
198 % 10 = 8
So 916179-87-8 is a valid CAS Registry Number.
916179-87-8Relevant articles and documents
TREATMENT OF PROTEIN FOLDING DISORDERS
-
Page/Page column 94-95, (2010/11/25)
In certain embodiments, the invention is directed to a method for treating a protein folding disorder such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathy. The method comprises the administration to a subject of a compound of the formula (I) wherein A and B are independently a mono- or bicyclic aromatic group or heteroaromatic cyclic group. In preferred embodiments, the compounds are bis-indole compounds.